Abstract
Background: Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related hospitalization and mortality.
Methods: This historical cohort study included members of a large health provider in Israel that were vaccinated with at least 1 dose of BNT162b2. The primary outcome was incidence rate of a SARS-CoV-2 infection confirmed with real-time polymerase chain reaction (rt-PCR), between 7 and 27 days after second dose (protection-period), as compared to days 1-7 after the first dose, where no protection by the vaccine is assumed (reference-period).
Results: Data of 1 178 597 individuals vaccinated with BNT162b2 were analyzed (mean age 47.7 years [SD = 18.1], 48.4% males) of whom 872 454 (74.0%) reached the protection period. Overall, 4514 infections occurred during the reference period compared to 728 during the protection period, yielding a weighted mean daily incidence of 54.8 per 100 000 (95% confidence interval [CI]: 26.1-115.0 per 100 000) and 5.4 per 100 000 (95% CI: 3.5-8.4 per 100 000), respectively. The vaccine effectiveness in preventing infection was 90% (95% CI: 79%-95%) and 94% (95% CI: 88%-97%) against COVID-19. Among immunosuppressed patients, vaccine effectiveness against infection was 71% (95% CI: 37%-87%). The adjusted hazard ratios for hospitalization in those infected were 0.82 (95% CI: .36-1.88), 0.45 (95% CI: .23-.90), and 0.56 (95% CI: .36-.89) in the age groups 16-44, 45-64. and ≥75 years, respectively.
Conclusions: The effectiveness of the BNT162b2 vaccine is comparable to the one reported in the phase III clinical trial.
Keywords: BNT162b2; COVID-19; effectiveness; real-world data; vaccine.
【저자키워드】 COVID-19, Vaccine, real-world data, BNT162b2, Effectiveness, 【초록키워드】 coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Vaccine, BNT162b2 vaccine, coronavirus, clinical trial, Randomized controlled trials, Mortality, Hospitalization, SARS-COV-2 infection, Infection, real-world data, severe acute respiratory syndrome Coronavirus, RT-PCR, cohort study, BNT162b2, Randomized, polymerase chain reaction, Health, mRNA, real-time polymerase chain reaction, incidence rate, age, incidence, group, immunosuppressed patients, Evidence, dose, Immunosuppressed, Chain Reaction, Messenger RNA, acute respiratory syndrome, Primary outcome, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, 95% confidence interval, adjusted hazard ratio, second dose, first dose, individual, adjusted hazard ratios, males, polymerase chain, shown, analyzed, evaluate, occurred, reported, the disease, comparable, reached, the vaccine, assumed, of BNT162b2, preventing infection, yielding,